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Dendrimeric macromolecules are synthetic and spherical systems that
have been attracting great deal of attention as nanocarriers for intracel-
lular drug delivery (DDS) [1]. These possess several advantages as
nanocarriers, as it possibly incorporating smart functionalities such as
targetability and stimuli-responsive drug release. Our group has been
proposing the use of dexamethasone (Dex)-loaded carboxymethylchi-
tosan/polyamidoamine dendrimer nanoparticles (CMCht/PAMAM
NPs) [2,3] for controlling the differentiation of stem cells towards the
osteogenic lineage. In this work, the biocompatibility of the Dex-loaded
CMCht/PAMAM NPs were investigated, in vitro and in vivo. CMCht/PA-
MAM NPs were produced as described by Oliveira et al. [4]. Dexameth-
asone (Dex) was loaded into the NPs by means of using a precipitation
route. Dex-loaded NPs were chemically bound to fluorescein isothiocy-
anate (FITC) for styding their intracellular fate. The cellular uptake of
NPs was investigated using different cell types namely rat bone marrow
stromal cells (RBMSCs) and Human Osteosarcoma cell line (SaOS-2),
for times up to 14 days of culturing. The internalization of the FITC-
labelled and Dex-loaded CMCht/PAMAM dendrimer NPs waere investi-
gated using fluorescence microscopy and flow cytometry (FACS) analy-
ses. FITC-labelled NPs (1 lg/g and 10 lg/g) were injected
intraveneously on Wistar rats and its biodistribution in different organs
was evaluated up to 72 h. Results have revealed that Dex-loaded
CMCht/PAMAM dendrimer NPs are non-cytotoxic, in vitro and in vivo.
The in vivo studies also revealed that CMCht/PAMAM dendrimer NPs
are stable in circulation. The histological study has shown that NP’s are
uptaken by cells from different tissues/organs namely, brain, liver, kid-
ney and lung. This study has revealed that the dexamethasone-loaded
CMCht/PAMAM dendrimer nanoparticles are non-toxic and demon-
strated a great ability for being uptaken by different cell types. More-
over, we have demonstrated that the dexamethasone-loaded CMCht/
PAMAM dendrimer nanoparticles are able to control stem cells osteo-
genic differentiation. As a final conclusion, the developed nanocarriers
are advantageous as intracellular nanocarrier tools for preprogramming
the stem cells fate ex vivo. The developed dexamethasone-loaded
CMCht/PAMAM dendrimer nanoparticles showed great promise for
application in bone tissue engineering strategies as it allowed us to pro-
duce de novo bone tissue in vivo.
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Proliferation and differentiation of mesenchymal stem cell (MSCs) are
regulated by its ‘‘niches’’ - the specific microenvironment that accounts
for tissue maintenance and repair. Glycosaminoglycans (GAGs), as
components of niches, bind non-covalently growth factors and trigger
multiple downstream signaling pathways controlling cellular activities.
Unraveling the chemical structures of GAGs like hyaluronic acid (HA),
chondroitin sulfate (CS) and heparin (Hep) has shown that they all
have similar disaccharide units, but differ in the quantity and location
of sulfate groups, which greatly influences their interactions with pro-
teins and cells. Here we developed a 2D model to study GAG effects on
mesenchymal stem cells’ (MSCs) proliferation and differentiation,
which may pave the way for applications in tissue engineering. GAGs
were oxidized using periodate to generate dialdehydes, shown by FT-
IR and H1-NMR spectroscopy, which were covalently immobilized on
amino-silane modified substrate by reductive amination. Surface wetta-
bility increase after immobilization of hydrophilic ox-GAG molecules.
Swelling surfaces exhibited relative flatten to aggregated structures, as
investigated by AFM, with the increase of sulfation of immobilized mol-
ecules. Meanwhile the roughness increased from 0.35 nm to 1.42 nm.
Zeta-potentials of ox-GAGs immobilized surfaces decreased with ox-
HA<ox-CS<ox-Hep, indicating that the amount of sulfate groups
increased. Proliferation of multipotent C3H/10T1/2 mesenchymal
mouse cells was enhanced on ox-Hep while inhibited on ox-HA. Confo-
cal laser scanning microscopy images showed that cells on ox-Hep had
the largest spreading area, by 24% beyond the others, whereas the
smallest form factor of 0.59. Alizarin red-S staining showed that red
dye bonded to nodules on each surface, indicating osteogenic differen-
tiation in the presence of rhBMP-2, with ox-HA<ox-CS<<ox-Hep. It
can be assumed that the larger amount of sulfates on ox-Hep contrib-
uted to the binding of BMP-2, which protected active protein-glycan
complex from being suppressed by antagonists, thus significantly
enhance osteogenesis of MSCs. In summary, GAG immobilized surfaces
with growth factors can mimic natural ECM-protein interactions and
enhance growth factor activity, which seems to be a useful method to
engineer MSCs’ proliferation and differentiation for tissue repair and
regeneration.
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